Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases
2008

Effective Vaccine Against Breast Cancer Metastases

Sample size: 5 publication 10 minutes Evidence: high

Author Information

Author(s): Kim S H, Castro F, Gonzalez D, Maciag P C, Paterson Y, Gravekamp C

Primary Institution: California Pacific Medical Center Research Institute

Hypothesis

Can the delivery of the Mage-b vaccine using recombinant Listeria monocytogenes enhance its efficacy against breast cancer metastases?

Conclusion

The LM-LLO-Mage-b/2nd vaccine significantly reduced the number of breast cancer metastases by 96% compared to the saline group.

Supporting Evidence

  • Vaccination with LM-LLO-Mage-b/2nd reduced metastases by 96% compared to saline.
  • Strong Mage-b-specific CD8 T-cell responses were observed in vaccinated mice.
  • The vaccine did not affect the growth of primary tumors.

Takeaway

A new vaccine helped mice fight off breast cancer spread by making their immune system stronger.

Methodology

Mice were vaccinated with different strains of the Mage-b vaccine and then injected with breast cancer cells to test the vaccine's effectiveness against metastases.

Limitations

The vaccine did not affect the growth of primary tumors, indicating a limitation in its application.

Participant Demographics

Normal female Balb/c mice, 3 months old.

Statistical Information

P-Value

0.0005

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6604526

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication